Page last updated: 2024-12-07

coumarin 343

Description Research Excerpts Clinical Trials Roles Classes Pathways Study Profile Bioassays Related Drugs Related Conditions Protein Interactions Research Growth Market Indicators

Description

Coumarin 343, also known as 7-amino-4-methylcoumarin, is a fluorescent dye with a high quantum yield. It is widely used in various applications, including fluorescence microscopy, flow cytometry, and as a probe for biomolecule labeling. The compound exhibits bright blue fluorescence and is readily soluble in organic solvents. It is synthesized through a multi-step process involving the condensation of 7-amino-4-methylcoumarin with a suitable electrophilic reagent. The fluorescence properties of Coumarin 343 make it a valuable tool for studying biological processes and developing new diagnostic and therapeutic agents. Its high quantum yield and good photostability make it suitable for long-term imaging experiments. Studies on Coumarin 343 focus on its potential applications in bioimaging, drug delivery, and sensor development.'

coumarin 343: structure in first source [Medical Subject Headings (MeSH), National Library of Medicine, extracted Dec-2023]

Cross-References

ID SourceID
PubMed CID108770
CHEMBL ID2442512
CHEBI ID51941
SCHEMBL ID45609
MeSH IDM0550088

Synonyms (39)

Synonym
OPREA1_370773
einecs 259-824-6
coumarin 343, dye content 97 %
coumarin 519
coumarin 343
CHEBI:51941 ,
11-oxo-2,3,6,7-tetrahydro-1h,5h,11h-pyrano[2,3-f]pyrido[3,2,1-ij]quinoline-10-carboxylic acid
55804-65-4
STK409686
1h,5h,11h-[1]benzopyrano[6,7,8-ij]quinolizine-10-carboxylicacid, 2,3,6,7-tetrahydro-11-oxo-
AKOS000805664
ST069309
7ge3q7lwr9 ,
1h,5h,11h-(1)benzopyrano(6,7,8-ij)quinolizine-10-carboxylic acid, 2,3,6,7-tetrahydro-11-oxo-
unii-7ge3q7lwr9
2,3,6,7-tetrahydro-11-oxo-1h,5h,11h-(1)benzopyrano(6,7,8-ij)quinolizine-10-carboxylic acid
2,3,6,7-tetrahydro-11-oxo-1h,5h,11h-[1]benzopyrano[6,7,8-ij]quinolizine-10-carboxylic acid
bdbm50442718
chembl2442512 ,
1h,5h,11h-[1]benzopyrano[6,7,8-ij]quinolizine-10-carboxylic acid, 2,3,6,7-tetrahydro-11-oxo-
SCHEMBL45609
DTXSID9069051
11-oxo-2,3,5,6,7,11-hexahydro-1h-pyrano[2,3-f]pyrido[3,2,1-ij]quinoline-10-carboxylic acid
C2899
mfcd00051335
coumarin-343
F3308-1839
KCDCNGXPPGQERR-UHFFFAOYSA-N
BS-17241
Q27123015
A11569
AMY31162
1h,5h,11h-[1]benzopyrano[6,7,8-ij]quinolizine-10-carboxylic?acid,2,3,6,7-tetrahydro-11-oxo-
4-oxo-3-oxa-13-azatetracyclo[7.7.1.02,7.013,17]heptadeca-1,5,7,9(17)-tetraene-5-carboxylic acid
BP-27942
LCZC362
CS-0312751
1h,5h,11h-[1]benzopyrano[6,7,8-ij]quinolizine-10-carboxylic?acid, 2,3,6,7-tetrahydro-11-oxo-
coumarin 343 acid

Research Excerpts

Bioavailability

ExcerptReferenceRelevance
" Present work also suggests that properly optimized encapsulation in appropriate receptor pocket can enhance the bioavailability of drugs."( Effect of encapsulation in the anion receptor pocket of sub-domain IIA of human serum albumin on the modulation of pKa of warfarin and structurally similar acidic guests: a possible implication on biological activity.
Datta, S; Halder, M, 2014
)
0.4
[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Roles (1)

RoleDescription
fluorochromeA fluorescent dye used to stain biological specimens.
[role information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Drug Classes (1)

ClassDescription
7-aminocoumarinsAny member of the class of coumarins that contains a 7-amino-2H-chromen-2-one skeleton.
[compound class information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Protein Targets (1)

Inhibition Measurements

ProteinTaxonomyMeasurementAverageMin (ref.)Avg (ref.)Max (ref.)Bioassay(s)
Monocarboxylate transporter 4Homo sapiens (human)IC50 (µMol)0.73000.00100.36840.8600AID780538
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023]

Biological Processes (4)

Processvia Protein(s)Taxonomy
lactate transmembrane transportMonocarboxylate transporter 4Homo sapiens (human)
pyruvate catabolic processMonocarboxylate transporter 4Homo sapiens (human)
pyruvate transmembrane transportMonocarboxylate transporter 4Homo sapiens (human)
monocarboxylic acid transportMonocarboxylate transporter 4Homo sapiens (human)
[Information is prepared from geneontology information from the June-17-2024 release]

Molecular Functions (5)

Processvia Protein(s)Taxonomy
RNA bindingMonocarboxylate transporter 4Homo sapiens (human)
protein bindingMonocarboxylate transporter 4Homo sapiens (human)
monocarboxylic acid transmembrane transporter activityMonocarboxylate transporter 4Homo sapiens (human)
lactate:proton symporter activityMonocarboxylate transporter 4Homo sapiens (human)
pyruvate transmembrane transporter activityMonocarboxylate transporter 4Homo sapiens (human)
[Information is prepared from geneontology information from the June-17-2024 release]

Ceullar Components (6)

Processvia Protein(s)Taxonomy
plasma membraneMonocarboxylate transporter 4Homo sapiens (human)
membraneMonocarboxylate transporter 4Homo sapiens (human)
basolateral plasma membraneMonocarboxylate transporter 4Homo sapiens (human)
apical plasma membraneMonocarboxylate transporter 4Homo sapiens (human)
lateral plasma membraneMonocarboxylate transporter 4Homo sapiens (human)
nuclear membraneMonocarboxylate transporter 4Homo sapiens (human)
plasma membraneMonocarboxylate transporter 4Homo sapiens (human)
basolateral plasma membraneMonocarboxylate transporter 4Homo sapiens (human)
[Information is prepared from geneontology information from the June-17-2024 release]

Bioassays (4)

Assay IDTitleYearJournalArticle
AID780544Cytotoxicity against human SiHa cells in lactate-containing medium after 72 hrs by MTT assay2013Bioorganic & medicinal chemistry, Nov-15, Volume: 21, Issue:22
Synthesis and pharmacological evaluation of carboxycoumarins as a new antitumor treatment targeting lactate transport in cancer cells.
AID780538Inhibition of MCT4-mediated [14C]-lactate uptake in human SiHa cells in lactate-containing medium assessed as remaining lactate concentration in culture medium after 24 hrs by liquid scintillation counting2013Bioorganic & medicinal chemistry, Nov-15, Volume: 21, Issue:22
Synthesis and pharmacological evaluation of carboxycoumarins as a new antitumor treatment targeting lactate transport in cancer cells.
AID780520Ratio of alpha-cyano-4-hydroxycinnamate IC50 to compound IC50 for MCT4-mediated [14C]-lactate uptake in human SiHa cells in lactate-containing medium assessed as remaining lactate concentration in culture medium after 24 hrs by liquid scintillation counti2013Bioorganic & medicinal chemistry, Nov-15, Volume: 21, Issue:22
Synthesis and pharmacological evaluation of carboxycoumarins as a new antitumor treatment targeting lactate transport in cancer cells.
AID780545Cytotoxicity against human SiHa cells in glucose-containing medium after 72 hrs by MTT assay2013Bioorganic & medicinal chemistry, Nov-15, Volume: 21, Issue:22
Synthesis and pharmacological evaluation of carboxycoumarins as a new antitumor treatment targeting lactate transport in cancer cells.
[information is prepared from bioassay data collected from National Library of Medicine (NLM), extracted Dec-2023]

Research

Studies (20)

TimeframeStudies, This Drug (%)All Drugs %
pre-19900 (0.00)18.7374
1990's0 (0.00)18.2507
2000's0 (0.00)29.6817
2010's19 (95.00)24.3611
2020's1 (5.00)2.80
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Market Indicators

Research Demand Index: 30.89

According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be moderate demand-to-supply ratio for research on this compound.

MetricThis Compound (vs All)
Research Demand Index30.89 (24.57)
Research Supply Index3.04 (2.92)
Research Growth Index5.58 (4.65)
Search Engine Demand Index36.71 (26.88)
Search Engine Supply Index2.00 (0.95)

This Compound (30.89)

All Compounds (24.57)

Study Types

Publication TypeThis drug (%)All Drugs (%)
Trials0 (0.00%)5.53%
Reviews1 (5.00%)6.00%
Case Studies0 (0.00%)4.05%
Observational0 (0.00%)0.25%
Other19 (95.00%)84.16%
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]